call 1800 257 600 email [email protected]

Caitlin’s story: Finding the compassion in cancer

August 16, 2021

“I’ll never forget the look on the radiologists’ faces when I had my CT scan,” Caitlin said. 

“I just knew it would be bad news. I remember sitting in the room before the scan thinking, almost knowing, that this wouldn’t be my last time, that this was the first of many appointments I would have in a long journey.” 

Caitlin was correct. What she found out next would change her life forever. 

“I was diagnosed in February 2017 with a rare form of ovarian cancer. I was only 39 and my daughters had just turned two and four. For six months in the lead up I was experiencing a lot of fatigue and intense migraines. I felt dramatic as I thought I was dying. I just knew something was wrong,” Caitlin reflected. 

Unfortunately, ovarian cancer is very difficult to diagnose, with symptoms often mirroring those of PMS or IBS. Most women, like Caitlin, are diagnosed at advanced stages, when the disease is harder to treat. 

It was abdominal pains and changes in appetite that led to further investigations for Caitlin, with lesions on her liver revealing stage 3 ovarian cancer. This was soon categorised to stage 4 when doctors discovered the disease had spread through her diaphragm into the chest wall. However, like her diagnosis, Caitlin’s treatment was not straight forward. 

“They initially told me that I had high grade serous ovarian cancer, the most common type, so I began standard treatment which included weekly chemotherapy, followed by complicated surgery. I had a radical hysterectomy, my spleen and liver stripped, and all tumours removed, including those in my diaphragm,” Caitlin shared. 

But a post-surgery biopsy revealed that Caitlin actually had clear cell ovarian cancer, the rarest and deadliest of them all. 

“Doctors said to me that the pathology didn’t matter, that ‘we treat all ovarian cancers the same’, which was alarming. My cancer wasn’t behaving typically like clear cell either, so despite results there was the possibility that I still had high grade serous ovarian cancer. To this day I believe my cancer is actually a mix of both,” Caitlin continued. 

“I went along with the presumption that my pathology didn’t matter, but I was cautious, as I am a scientist by profession. I had also recently witnessed my mother in law pass away due to poor care, mainly owing to a lack of communication between health professionals.” 

It was during this time that Caitlin learnt the importance of advocating for herself within a complex health system. 

“I was lucky to receive world leading care at my holistic cancer hospital, where compassion is at the core of everything they do. This made a huge difference to my experience, and thankfully the surgery I had in May 2017, combined with six months of chemo, was a success. They were able to remove all of my visible disease. I then went on the maintenance treatment Avastin. As a stage 4 patient I was able to access it for free for one year, then I had to self-fund which cost $45,000 in my second year,” Caitlin said. 

“It was working really well and I remained cancer free for two years whilst on Avastin. At the time there was no data on the efficacy of Avastin beyond two years, so I was advised to stop it. Six months later, in Feburary 2020, when COVID crashed into our lives, my cancer reoccurred. It came back in my liver and lymph nodes. Chemotherapy didn’t work this time, which apparently is normal for clear cell ovarian cancer, but not what my team expected given my great initial response. This is when I was grateful to have pushed for genetic testing as I was running out of options. 

“I’m glad I did because these investigations revealed that the make-up of my cancer was extremely unique. It was confirmed that I do indeed have clear cell ovarian cancer. However, I also have genetic markers typical to high grade serous ovarian cancer.” 

One clinical trial offered hope but was quickly deemed unsuccessful. Due to her rare pathology, Caitlin is not a candidate for many clinical trials or PBS listed drugs which could prolong her life. Like all rare cancers, there are simply not enough people to warrant a trial, or to gather meaningful data, and by definition there never will be. But her clinical background and sheer determination drove her to keep advocating for herself, her life, and her family’s future.

“As a scientist, I knew I needed to find the most promising emerging science. I didn’t have time to wait for a suitable clinical trial and I didn’t want to go back on standard chemo that probably wouldn’t work. But even with my experience, I found I just couldn’t read scientific paper after paper. It was too close for me. It got overwhelming and stressful really quickly,” she said. 

“So I reached out to the leading clear cell ovarian cancer experts in the world, including a specialist in Singapore. He recommended a new off label drug combo, not yet trialed in Australia, that had shown good results for endometrial cancer. He thought that with my cancer’s genetic structure it would benefit me, and it did. 

“I started in July 2020 and I’ve remained stable ever since. None of my cancer has spread.” 

This drug combo includes immunotherapy (Pembrolizumab), which Caitlin has every three weeks, combined with a daily treatment that comes in tablet form called Lenvatinib, a VEG-F inhibitor similar to Avastin. It has been working well to keep her cancer at bay, however the side effects are crippling. 

“It has flared up my neuropathy, which is damage to my nerves from past chemo. This means I have difficulty walking and I’m in a lot of pain. Some days it feels like my feet have been burnt, especially as the skin is peeling off them,” Caitlin explained. 

“But the treatment is working so I need to keep going. However, it is extremely expensive as it is not government funded, costing $12,000 a month. Cancer is crippling – physically and financially. It’s frustrating because other people can access PBS funded lifesaving drugs if they have a different kind of cancer or a more common pathology. But because mine is rare I have to pay and be my own clinical trial.” 

Caitlin’s condition has recently progressed with two of the tumours in her liver growing. 

“I was keen to have radiotherapy on my growing tumours. No one initially offered it to me as it’s not standard treatment for ovarian cancer patients in Australia. Overseas they use it a lot for clear cell ovarian patients, with good results. I pushed for the treatment and in May I received it. It’s still too early to tell if it has worked, but so far my tumours have not shown any more signs of growth,” Caitlin told. 

“I’ve learnt a lot since having cancer, such as the importance of speaking up for yourself. Since being diagnosed I have advocated for better funding and awareness of ovarian cancer, for myself and all of those living with the disease. I even spoke at Parliament House to Scott Morrison earlier this year, pleading for more research funding and PBS listed drugs. But it upsets me that patients have to advocate so hard for themselves. It shouldn’t be that way. 

“This experience has also opened my eyes up to how sensitive and vulnerable you are as a patient. I’ve worked in health as an IVF scientist for many years, but it wasn’t until I was a patient myself that I appreciated how different your experience can be to that of the experience your healthcare team think you’re having. 

“For example, you don’t always hear or understand everything that people say when you are dealing with trauma. And words are so powerful. Depending on how and when you hear them, you can feel totally empowered or completely defeated. I don’t think that every member of the medical community appreciates the importance of good, patient-centric communication.” 

This is the reason why Caitlin started the initiative CareFully. 

“I launched CareFully last year to support and train healthcare professionals on the power of compassion, as well as to empower patients to advocate for themselves,” she shared. 

Caitlin’s approach is unique in that she uses her dual insight as a both a health professional and patient to educate on the importance of compassion in healthcare, self-awareness, good communication, and patient-centred care. 

“I love what I do. It gives me purpose and makes me feel like I can use my traumatic experience to create something good and help others,” she continued. 

Caitlin is also doing well from a health perspective. 

“I’m going pretty strong. It’s four and half years since my diagnosis and I’ve almost smashed the five year survival rate for ovarian cancer,” she said. 

“I hate cancer. It’s always there and on everyone’s minds, including my young kids. It has taken over our lives, and I hate that everything can so quickly become about me. 

“But I try and lead a pretty normal life for my family. While the future is uncertain and my daughters still ask me why I have cancer, I’m grateful that I’m still here to answer that question. 

“What I want people to know from all of this is that there is hope, and it can be found in the places you least expect. Don’t be afraid to think outside the box.”

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.